-
Angiotensin I Workflows for RAS Research
2026-09-03
Use Angiotensin I as a controllable substrate to dissect renin–angiotensin system research, quantify ACE-dependent conversion, and improve antihypertensive drug screening. This workflow also clarifies when a decapeptide challenge is informative in cardiovascular, neuroendocrine, and emerging peptide–receptor binding assays.
-
How Near-Death Tumor Cells Become Metastatic
2026-09-03
Conod, Silvano, and Ruiz i Altaba identify a mechanism by which tumor cells that survive impending death acquire stable prometastatic properties. Their study defines PAMEs, links their formation to ER stress and nuclear reprogramming, and shows that a cytokine-driven interaction with neighboring cells creates a broader prometastatic ecosystem.
-
LRG1 and Neutrophil Mitochondria in Bladder Cancer
2026-09-02
The Advanced Science study identifies an LRG1–ANXA2–neutrophil pathway that links tumor-derived LRG1 to mitochondrial stress, NET release, vascular destabilization, and treatment resistance in bladder cancer. Its integrated single-cell, molecular, and in vivo strategy suggests that disrupting NETosis may normalize tumor vessels and improve responses to cisplatin and anti-PD-1 therapy.
-
Non-Betalain DODA and Stress Adaptation in Pansy
2026-09-02
A 2025 study shows that VwDODA, a non-betalain DODA homolog from pansy, has a stress-related metabolic role rather than a canonical pigment-producing function. Through biochemical, heterologous-expression, and promoter analyses, the authors link VwDODA to salt tolerance, pathogen resistance, antioxidant defense, ABA signaling, and VwMYB20-associated regulation.
-
PPT (Propyl Pyrazole Triol): ERα Research Guide
2026-09-01
PPT (Propyl Pyrazole Triol) is a potent, selective ERα agonist for separating estrogen receptor alpha signaling from ERβ activity in research models. B6735 combines strong reported subtype preference with defined solvent, storage, gene-expression, and uterotrophic assay information.
-
BCL6–ESM1 Axis in Hepatocellular Carcinoma Immunity
2026-09-01
The reference study identifies cancer-cell BCL6 as an immune-evasion regulator in hepatocellular carcinoma, linking reduced inflammatory signaling and increased ESM1 to impaired tumor-infiltrating CD4+ T-cell recruitment and cytotoxicity. Its findings shift attention beyond CD8+ T-cell quantity toward CD4+ T-cell function and suggest a paracrine mechanism that may influence future combination immunotherapy research.
-
Diminazene Aceturate Research Workflows
2026-08-31
Diminazene Aceturate supports two distinct research tracks: trypanosome parasite screening and mechanistic ACE2 activation studies. This workflow-focused guide covers stock preparation, assay design, cross-domain interpretation, and troubleshooting without treating antiparasitic activity as proof of mitochondrial protection.
-
Hexa His tag peptide for cleaner IP workflows
2026-08-31
The Hexa His tag peptide enables antibody-compatible, competitive elution of His-tagged proteins while minimizing immunoglobulin heavy- and light-chain carryover. This practical guide covers assay setup, quantitative starting conditions, interaction studies, troubleshooting, and how emerging sequence-based binding models may inform future validation strategies.
-
DIDS: Chloride Transport Workflows for Cancer Research
2026-08-30
DIDS connects chloride-channel pharmacology with near-death cancer-cell models, enabling researchers to test how mitochondrial death signaling influences prometastatic phenotypes. This guide combines practical dosing, solubility control, orthogonal readouts, and cross-domain applications in vascular, sensory, and neurobiology research.
-
Quizartinib (AC220) AML Workflow Guide
2026-08-29
Build reproducible FLT3 signaling, viability, and xenograft workflows with Quizartinib (AC220), from DMSO stock preparation through orthogonal validation. The guide also shows how lessons from a norovirus secretion study can sharpen assay controls without conflating antiviral biology with AML pharmacology.
-
MFGE8–ANXA1–SMAD2/3 in Pancreatic Fibrosis
2026-08-28
This study presents a multimodal strategy for chronic pancreatitis that combines umbilical cord-derived mesenchymal stem cells, their extracellular vesicles, and recombinant MFGE8 nanoparticles. Its central contribution is the identification of an MFGE8-dependent ANXA1–SMAD2/3 mechanism that links extracellular-vesicle activity to reduced pancreatic stellate-cell fibrosis and improved disease features in mice.
-
SIX1 Drives De Novo Lipogenesis in Liver Cancer
2026-08-28
The reference study identifies SIX1 as a direct transcriptional driver of de novo lipogenesis in liver cancer cells, linking ACLY, FASN, and SCD1 expression to AIB1 and HBO1/KAT7-dependent chromatin regulation. It also defines an insulin-responsive DGUOK-AS1–miR-145-5p–SIX1 axis that connects lipid synthesis with tumor proliferation, invasion, metastasis, and patient prognosis.
-
PRINT: RNA-Mediated Transgene Insertion at Safe Harbors
2026-08-27
Zhang and colleagues introduce PRINT, an RNA-only strategy that repurposes avian R2 retroelement proteins for site-specific transgene insertion at a multicopy human safe-harbor locus. The study combines target-primed reverse transcription with two in vitro transcribed RNAs and reports efficient, substantially full-length insertion in cultured human primary cells without a DNA donor.
-
Tranexamic Acid in Fibrinolysis Research
2026-08-27
Tranexamic Acid connects plasmin biology to practical clot-stability assays and next-generation wound-dressing models. This guide covers concentration planning, assay controls, formulation translation, and troubleshooting for reproducible inhibition of fibrinolysis.
-
Novobiocin Workflows for Antimicrobial Research
2026-08-26
Novobiocin is an aminocoumarin antibiotic that supports comparative bacterial susceptibility testing as well as antiparasitic, antiviral, and host-protein studies. This practical guide converts published staphylococcal findings into reproducible bench workflows, decision points, and troubleshooting strategies.